Please login to the form below

Not currently logged in


This page shows the latest Orphacol news and features for those working in and with pharma, biotech and healthcare.

EC sets up expert group on rare diseases

EC sets up expert group on rare diseases

approve a previously-rejected drug - CTRS' Orphacol - earlier this month.

Latest news

  • Court orders EC to approve rejected orphan medicine Court orders EC to approve rejected orphan medicine

    Says CTRS should be allowed to market Orphacol for the treatment of rare bile condition. ... The battle pitched small French pharma company Cell Therapies Research &Services (CTRS) against the Commission and focused on Orphacol (cholic acid), a drug

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...